全文获取类型
收费全文 | 293篇 |
免费 | 25篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 37篇 |
口腔科学 | 69篇 |
临床医学 | 53篇 |
内科学 | 68篇 |
皮肤病学 | 1篇 |
神经病学 | 7篇 |
特种医学 | 12篇 |
外科学 | 25篇 |
综合类 | 1篇 |
预防医学 | 15篇 |
眼科学 | 1篇 |
药学 | 9篇 |
肿瘤学 | 11篇 |
出版年
2023年 | 3篇 |
2021年 | 4篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 4篇 |
2013年 | 3篇 |
2012年 | 7篇 |
2011年 | 16篇 |
2010年 | 7篇 |
2009年 | 5篇 |
2008年 | 15篇 |
2007年 | 25篇 |
2006年 | 16篇 |
2005年 | 17篇 |
2004年 | 11篇 |
2003年 | 19篇 |
2002年 | 13篇 |
2001年 | 21篇 |
2000年 | 14篇 |
1999年 | 13篇 |
1998年 | 7篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1971年 | 1篇 |
1966年 | 1篇 |
1931年 | 1篇 |
1929年 | 1篇 |
1923年 | 1篇 |
1921年 | 1篇 |
排序方式: 共有318条查询结果,搜索用时 31 毫秒
1.
A pulmonary metastasis of prostate cancer in the absence of osseous or lymph node metastases is an extremely rare finding. We report the case of a 49-year-old man with a history of stage T2CN0M0 prostate cancer who had undergone a radical perineal prostatectomy and laparoscopic lymph node dissection, pelvic radiotherapy, and hormonal manipulation. He developed a solitary pulmonary nodule with a negative bone scan and computed tomography of his chest, abdomen, and pelvis. As a result, he underwent an open biopsy and lobectomy. The final pathology of the specimen was consistent with a metastatic lesion that stained positive for prostate-specific antigen. We present this unusual case and a review of the small number of similar cases that have been reported. 相似文献
2.
3.
4.
5.
OBJECTIVES: All dental surgeons should be protected from hepatitis B virus (HBV) infection by immunisation, ideally administered and monitored via occupational health services (OHS). This study examined relevant OHS systems in place for dental primary care healthcare workers (DHCW) across all Health Board Areas (HBAs) in Scotland. It also explored the DHCWs' knowledge of, and access to, these systems in three HBAs. METHODS: Data from senior staff in all Scottish Health Boards and Primary Care Trusts were collected by self-completing questionnaires. Information from DHCWs was collected via telephone interviews with General Dental Practitioners (GDPs) and Community Dental Officers (CDOs) in each of Ayrshire and Arran, Highland and Lothian Health Boards. RESULTS: Thirteen of the 15 HBAs had robust HBV vaccination and monitoring systems. However, only 7/15 (47%) of these covered all DHCWs. Seven HBAs provided vaccination and monitoring for CDOs only, leaving GDPs to undertake these responsibilities for themselves. Of the 105 DHCWs approached, 82 gave an interview. These interviews highlighted major differences between HBAs in relation to access of DHCWs to OHS and indicated that CDOs had greater access than GDPs to OHS. Overall, 31% of DHCWs were not satisfied with the OHS available. CONCLUSION: In order to safeguard both staff and patients, significant further work is required to ensure that all DHCWs have access to appropriate OHS support for provision and monitoring of immunisation procedures and related functions such as management of sharps injuries. 相似文献
6.
7.
Carvajal-Cuenca A Sua LF Silva NM Pittaluga S Royo C Song JY Sargent RL Espinet B Climent F Jacobs SA Delabie J Naresh KN Bagg A Brousset P Warnke RA Serrano S Harris NL Swerdlow SH Jaffe ES Campo E 《Haematologica》2012,97(2):270-278
Background
Cyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called “in situ mantle cell lymphoma”. The clinical significance of this lesion remains uncertain.Design and Methods
The clinical and pathological characteristics, including SOX11 expression, of 23 cases initially diagnosed as in situ mantle cell lymphoma were studied.Results
Seventeen of the 23 cases fulfilled the criteria for in situ mantle cell lymphoma. In most cases, the lesions were incidental findings in reactive lymph nodes. The t(11;14) was detected in all eight cases examined. SOX11 was positive in seven of 16 cases (44%). Five cases were associated with other small B-cell lymphomas. In two cases, both SOX11-positive, the in situ mantle cell lymphoma lesions were discovered after the diagnosis of overt lymphoma; one 4 years earlier, and one 3 years later. Twelve of the remaining 15 patients had a follow-up of at least 1 year (median 2 years; range, 1–19.5), of whom 11 showed no evidence of progression, including seven who were not treated. Only one of 12 patients with an in situ mantle cell lymphoma lesion and no diagnosis of mantle cell lymphoma at the time developed an overt lymphoma, 4 years later; this case was also SOX11-positive. The six remaining cases were diagnosed as mantle cell lymphoma with a mantle zone pattern. Five were SOX11-positive and four of them were associated with lymphoma without a mantle zone pattern.Conclusions
In situ mantle cell lymphoma lesions are usually an incidental finding with a very indolent behavior. These cases must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because they may not require therapeutic intervention. 相似文献8.
9.
10.
Donald E Tsai Selina M Luger Charalambos Andreadis Dan T Vogl Allison Kemner Melissa Potuzak Ami Goradia Alison W Loren Alexander E Perl Stephen J Schuster David L Porter Edward A Stadtmauer Steven C Goldstein James E Thompson Cezary Swider Adam Bagg Anthony R Mato Martin Carroll 《Clinical cancer research》2008,14(17):5619-5625
PURPOSE: Bexarotene is a retinoic X receptor agonist that has been shown in vitro to inhibit growth and induce differentiation of myeloid leukemic cell lines. We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML). EXPERIMENTAL DESIGN: We enrolled patients with active non-M3 AML who had either relapsed or refractory disease or were not eligible for standard cytotoxic chemotherapy. Cohorts of three to six patients received escalating doses of daily oral bexarotene ranging from 100 to 400 mg/m(2) until evidence of disease progression or unacceptable adverse events occurred. RESULTS: Twenty-seven patients, with median age of 69 years (range, 51-82 years), were treated. Twenty-four (89%) patients had undergone prior chemotherapy. At the highest dose level tested (400 mg/m(2)), three of six patients had to reduce their dose of bexarotene due to grade 3 adverse events. The maximum tolerable dose of bexarotene was determined to be 300 mg/m(2). Clinical activity was manifested by 4 (15%) patients with reduction in bone marrow blasts to 1 year while taking bexarotene. Leukemic blast differentiation was suggested by the presence of the leukemic cytogenetic abnormality in mature circulating granulocytes and the occurrence of differentiation syndrome. CONCLUSIONS: The recommended dose of bexarotene for future studies is 300 mg/m(2)/d. Bexarotene is well tolerated in patients with non-M3 AML and has evidence of antileukemic activity. 相似文献